L. Lombard

A 24-week, prospective, randomized, open-label, treat-to-target pilot study of obese type 2 diabetes patients with severe insulin resistance to assess the addition of exenatide on the efficacy of u-500 regular insulin plus metformin.

A. Amod, L. Distiller, H. Nortje, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.

M. Jaros, F. Raal, L. Burgess, 2022, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

A cross‐sectional study of the prevalence and clinical management of atherosclerotic cardiovascular diseases in patients with type 2 diabetes across the Middle East and Africa (PACT‐MEA): Study design and rationale

W. Almahmeed, S. Assaad-Khalil, S. Salek, 2023, Diabetes, obesity & metabolism.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.